ACTRN12605000536662进行中（未招募）2 期
Phase II study to assess the safety and efficacy of allogeneic transplantation using transplant-lite conditioning regimes (Fludarabine and Melphalan) in patients with a diagnosis of a haematological malignancy or metastatic renal cancer who are considered unsuitable for a standard conditioning regime due to age, poor physical status or previous exposure to high dose chemotherapy/radiotherapy.
Dr James Morton0 个研究点目标入组 80 人开始时间: 2005年9月28日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- ot stated 至 70 Years（—）
- 性别
- All
入选标准
- •Summary of Patient/Donor Eligibility Criteria:1. Diagnosis of haematological malignancy or metastatic renal cancer. 2. ECOG performance status 0-2. 3. Either a suitable HLA-identical sibling donor, fit for peripheral blood stem cell collection (cohort 1) or a suitable HLA-mismatched (single HLA mismatch) sibling donor, fit for peripheral blood stem cell collection, available HLA-identical (HLA-A,B,DRB1) unrelated donor or available HLA-mismatched (single HLA mismatch) unrelated donor (cohort 2).
排除标准
- •No exclusion criteria
研究者
相似试验
已完成
2 期
A phase II study to evaluate efficacy and safety of Bevacizumab combined with Cisplatin and S-1 for Advanced Non-Squamous Non-Small-Cell Lung Cancernon-squamous non-small-cell lung cancerJPRN-UMIN000009476The Tokyo cooperative oncology group39
招募中
2 期
Trifluridine/tipiracil (FTD/TPI) plus ramucirumab (Ram) for advanced gastric cancerGastric cancergastric cancerJPRN-jRCTs041210105Kodera Yasuhiro32
已完成
2 期
Phase II study investigating efficacy and safety of TFTD plus bevacizumab by RAS mutation status in patients with unresectable advanced or recurrent colorectal cancer refractory or intolerant to standard chemotherapyColorectal cancerJPRN-UMIN000030077Japanese Foundation for Multidisciplinary Treatment of Cancer102
进行中（未招募）
不适用
Safety and efficacy of combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with metastatic melanomaStage IV MelanomaMedDRA version: 14.0Level: PTClassification code 10025671Term: Malignant melanoma stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-019033-98-DEniversity Clinical Center of Tuebingen
已完成
2 期
Phase II study assessing the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)JPRN-UMIN000020773Translational Research Informatics Center, Foundation for Biomedical Research and Innovation39